Want a biotech buyout? Target cancer

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hope you had a reflective Indigenous Peoples Day. Today, we talk about the implications of Bristol Myers Squibb acquiring Mirati Therapeutics, see a new lung cancer test from liquid biopsy player Delfi Diagnostics, and more.

The need-to-know this morning
• Akero Therapeutics said its experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease. Adam Feuerstein has more details on the study outcome, and why Akero exeutives remains confident in the efficacy of its drug for patients with NASH cirrhosis. Investors are less sanguine: Akero shares are plunging in pre-market trading.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In